Literature DB >> 35422900

Identification of a tripartite motif family gene signature for predicting the prognosis of patients with glioma.

Sheng Xiao1,2, Junhua Yu2, Xuegang Yuan2, Qianxue Chen1.   

Abstract

Objectiove: The tripartite motif (TRIM) family genes, which encode a protein subfamily of the RING type E3 ubiquitin ligases, function as important regulators of oncogenesis and development. It is thus of great importance to investigate the potential value of the TRIM family genes for prognostic prediction in glioma.
METHODS: The gene expression RNA-Seq data and corresponding clinical information of glioma patients were obtained from The Cancer Genome Atlas (TCGA) dataset and the Chinese Glioma Genome Atlas (CGGA) dataset. LASSO regression and multivariate Cox regression analyses were performed to construct a risk signature of the TRIM family genes. The accuracy of the risk signature in predicting the prognosis of glioma patients was evaluated. The effects of TRIM17 on glioma cell proliferation were further explored.
RESULTS: We constructed a prognostic signature based on eight TRIMs for the prediction of overall survival of glioma patients. Internal and external cohorts confirmed the satisfactory accuracy and generalizability of the signature in predicting the prognosis of glioma patients. Of the eight TRIMs, TRIM17 was significantly downregulated in glioma, and decreased with an increase in the tumor grade. Moreover, low expression of TRIM17 predicted poor prognosis in glioma. CCK-8 and colony formation assays indicated that TRIM17 overexpression significantly inhibited cell proliferation. Conversely, silencing of TRIM17 had the opposite effects.
CONCLUSION: Our eight-gene signature based on the TRIM gene family is a novel and clinically useful biomarker, which may be helpful for clinical decision-making. Additionally, TRIM17 might be a therapeutic target for glioma. AJTR
Copyright © 2022.

Entities:  

Keywords:  TRIM17; Tripartite motif family; glioma; prognosis; proliferation; signature

Year:  2022        PMID: 35422900      PMCID: PMC8991143     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  35 in total

1.  TRIM67 Activates p53 to Suppress Colorectal Cancer Initiation and Progression.

Authors:  Shiyan Wang; Yanquan Zhang; Junzhe Huang; Chi Chun Wong; Jianning Zhai; Chuangen Li; Guifeng Wei; Liuyang Zhao; Guoping Wang; Hong Wei; Zengren Zhao; Jun Yu
Journal:  Cancer Res       Date:  2019-06-25       Impact factor: 12.701

Review 2.  The interferon-stimulated gene TRIM22: A double-edged sword in HIV-1 infection.

Authors:  Elisa Vicenzi; Guido Poli
Journal:  Cytokine Growth Factor Rev       Date:  2018-02-10       Impact factor: 7.638

3.  Trim17-mediated ubiquitination and degradation of Mcl-1 initiate apoptosis in neurons.

Authors:  M M Magiera; S Mora; B Mojsa; I Robbins; I Lassot; S Desagher
Journal:  Cell Death Differ       Date:  2012-09-14       Impact factor: 15.828

4.  TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.

Authors:  Ke Li; Feng Wang; Wen-Bin Cao; Xiao-Xi Lv; Fang Hua; Bing Cui; Jiao-Jiao Yu; Xiao-Wei Zhang; Shuang Shang; Shan-Shan Liu; Jin-Mei Yu; Ming-Zhe Han; Bo Huang; Ting-Ting Zhang; Xia Li; Jian-Dong Jiang; Zhuo-Wei Hu
Journal:  Cancer Cell       Date:  2017-05-08       Impact factor: 31.743

Review 5.  Current and future strategies for treatment of glioma.

Authors:  Nancy Ann Oberheim Bush; Susan M Chang; Mitchel S Berger
Journal:  Neurosurg Rev       Date:  2016-04-16       Impact factor: 3.042

Review 6.  Conserved structural and functional aspects of the tripartite motif gene family point towards therapeutic applications in multiple diseases.

Authors:  Liubov V Gushchina; Thomas A Kwiatkowski; Sayak Bhattacharya; Noah L Weisleder
Journal:  Pharmacol Ther       Date:  2017-10-31       Impact factor: 12.310

7.  MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.

Authors:  Alireza Mansouri; Laureen D Hachem; Sheila Mansouri; Farshad Nassiri; Normand J Laperriere; Daniel Xia; Neal I Lindeman; Patrick Y Wen; Arnab Chakravarti; Minesh P Mehta; Monika E Hegi; Roger Stupp; Kenneth D Aldape; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2019-02-14       Impact factor: 12.300

8.  TRIM8 downregulation in glioma affects cell proliferation and it is associated with patients survival.

Authors:  Lucia Micale; Carmela Fusco; Andrea Fontana; Raffaela Barbano; Bartolomeo Augello; Pasquelena De Nittis; Massimiliano Copetti; Maria Teresa Pellico; Barbara Mandriani; Dario Cocciadiferro; Paola Parrella; Vito Michele Fazio; Lucia Maria Cecilia Dimitri; Vincenzo D'Angelo; Chiara Novielli; Lidia Larizza; Antonio Daga; Giuseppe Merla
Journal:  BMC Cancer       Date:  2015-06-16       Impact factor: 4.430

9.  Tripartite motif-containing 14 (TRIM14) promotes epithelial-mesenchymal transition via ZEB2 in glioblastoma cells.

Authors:  Shuang Feng; Xiaomin Cai; Yangyang Li; Xiaoguang Jian; Linxin Zhang; Bin Li
Journal:  J Exp Clin Cancer Res       Date:  2019-02-06

Review 10.  Targeting Chemoresistant Tumors: Could TRIM Proteins-p53 Axis Be a Possible Answer?

Authors:  Alessio Valletti; Flaviana Marzano; Graziano Pesole; Elisabetta Sbisà; Apollonia Tullo
Journal:  Int J Mol Sci       Date:  2019-04-10       Impact factor: 5.923

View more
  2 in total

Review 1.  TRIM family contribute to tumorigenesis, cancer development, and drug resistance.

Authors:  Ning Huang; Xiaolin Sun; Peng Li; Xin Liu; Xuemei Zhang; Qian Chen; Hong Xin
Journal:  Exp Hematol Oncol       Date:  2022-10-19

2.  Construction and validation of an angiogenesis-related gene expression signature associated with clinical outcome and tumor immune microenvironment in glioma.

Authors:  Tianhao Hu; Yutao Wang; Xiaoliang Wang; Run Wang; Yifu Song; Li Zhang; Sheng Han
Journal:  Front Genet       Date:  2022-08-11       Impact factor: 4.772

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.